Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
Conditions
Parkinson Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Cedars-Sinai Department of Neurology, Los Angeles, California, United States
University of California San Francisco, San Francisco, California, United States
Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Ichan School of Medicine at Mount Sinai/Beth Israel Downtown-Movement Disorder Center, New York, New York, United States
Evergreen Health Laboratory, Kirkland, Washington, United States
Inland Northwest Research, Spokane, Washington, United States
Technische Universität Dresden, Dresden, Germany
University of Lübeck, Lübeck, Germany
University Hospital Tübingen, Tübingen, Germany
Rabin Medical Center, Petah Tikva, Israel
Movement Disorders Institute, Sheba Medical Center, Ramat Gan, Israel
Tel Aviv Medical Center, Tel Aviv, Israel
Hospital Clinic de Barcelona, Barcelona, Spain
Hospital Universitari General de Catalunya, Barcelona, Spain
Hospital Universitari Vall d'Hebron, Barcelona, Spain
Hospital Universitario Donostia, Donostia / San Sebastian, Spain
Universitary Hospital La Princesa, Madrid, Spain
IDIVAL/University Hospital Marques de Valdecilla, Santander, Spain
Hospital Universitario Virgen del Rocio, Seville, Spain
Study leads
Danna Jennings, MD
Study Director
Denali Therapeutics